Skip to main content

Profile Image

Staff Clinician

Edjah Nduom, M.D.

Surgical Neurology Branch

Building 10 Room 3D-20
Center Drive
Bethesda MD 20892
Office: (301) 496-2921
Lab: (301) 402-0380

Dr. Edjah Nduom is a fellowship-trained neurosurgical oncologist in the Surgical Neurology Branch of the NINDS. He joined the faculty as a Staff Clinician in August 2015. Dr. Nduom obtained his B.S. in Biomechanical Engineering at Stanford University in 2002 and subsequently obtained his M.D. from the University of Pennsylvania in 2006. He then pursued Neurosurgical training in the Department of Neurosurgery at Emory University. During residency, he was awarded an NIH R25 Research Development Grant to study the delivery of nanoparticles to the brain for the treatment of brain tumors with Costas Hadjipanayis, M.D., Ph.D. He completed an in-folded Research Fellowship in Neurosurgical Oncology with Dr. Russell Lonser in the Surgical Neurology Branch in 2012. There, he focused on convection-enhanced delivery for drug delivery to the brain and the characterization of the blood-brain barrier of malignant brain lesions. Dr. Nduom completed his neurosurgical training in 2013 and then pursued an additional Neurosurgical Oncology Fellowship at UT MD Anderson Cancer Center in Houston, Texas, where he was awarded the Jesse H. Jones Fellowship in Cancer Education. While at MD Anderson, Dr. Nduom spent a year in the laboratory of Amy Heimberger, M.D., studying microRNAs with immune modulatory properties for the treatment of brain tumors. In his second year, he obtained further training in the resection of brain and spinal tumors under the tutelage of Raymond Sawaya, M.D. and Jeffrey Weinberg, M.D.

Dr. Nduom’s clinical specialty is the surgical management of brain and spinal cord tumors, and he is particularly interested in the safe resection of malignant tumors located in eloquent areas of the brain, the brainstem and spinal cord. His research focuses on the modulation of the immune system for the treatment of malignant brain tumors.

Dr. Nduom’s work attempts to harness the power of the immune system to fight brain tumors. The immune system is the body’s primary way of fighting off infections, but it is also constantly monitoring the cells of our bodies for abnormalities. In this way, the immune system is also the front line of defense against the abnormal cells of cancer. Unfortunately, many cancers have found ways to hide themselves from the immune system. In the attached figure, you can see the many ways that brain tumors send signals that shut down the effector T cells that the immune system sends to fight tumors.

Nduom Research

By studying the many ways that tumors hide themselves in patients, I help discover ways that we can evade these defenses and use the body’s own defenses to ward off cancer.

Recent and ongoing projects include:

  • Identifying the frequency and prognostic relevance of the expression of the immunosuppressive ligand, Programmed Death-Ligand 1, in glioblastoma patient tissue (Nduom et al., Neuro-Oncology, 2016; Pratt et al. Neurosurgery, 2018)
  • The development of a clinical trial to use cerebral microdialysis to determine the response to me-adjuvant immune checkpoint inhibition in recurrent glioblastoma patients (Lynes et al., Neurosurgery, 2018; NCT03493932:
  • Pre-clinical work to discover better combinations of immune modulatory treatments to improve effector T-cell infiltration for the treatment of glioblastoma

Staff Image
  • 1) Lynes J, Jackson S, Sanchez V, Dominah G, Wang X, Kuek A, Hayes CP, Benzo S, Scott GC, Chittiboina P, Zaghloul KA, Park DM, Wu J, Hourigan CS, Giles AJ, Wu T, Maric D, Chen J, Quezado M, Heiss JD, Gilbert MR, Nduom EK. (2019)
  • Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint Blockade
  • Neurosurgery, 84, 945–953
  • 2) Pratt D, Dominah G, Lobel G, Obungu A, Lynes J, Sanchez V, Adamstein N, Wang X, Edwards NA, Wu T, Maric D, Gilbert MR, Quezado MM, Nduom EK (2018)
  • Programmed Death Ligand 1 Is a Negative Prognostic Marker in Recurrent Isocitrate Dehydrogenase-Wildtype Glioblastoma
  • Neurosurgery, Jul 12; doi: 10.1093/neuros/nyy268
  • 3) Jackson S, Weingart J, Nduom EK, Harfi T, George RT, McAreavey D, Ye X, Anders NM, Peer C, Figg WD, Gilbert MR, Rudek MA, Grossman SA (2018)
  • The Effect of an Adenosine A2A Agonist on Intra-Tumoral Concentrations of Temozolomide in Patients with Recurrent Glioblastoma
  • Fluids Barriers CNS, 2018 Jan 15;15(1):2, doi: 10.1186/s12987-017-0088-8
  • 4) Wei J*, Nduom EK*, Kong LY, Hashimoto Y, Xu S, Gabrusiewicz K, Ling X, Huang N, Qiao W, Zhou S, Ivan C, Fuller GN, Gilbert MR, Overwijk W, Calin GA, Heimberger AB (2016)
  • MiR-138 exerts anti-glioma efficacy by targeting immune checkpoints
  • Neuro Oncol, 2016 May;18(5):639-48, doi: 10.1093/neuonc/nov292. Epub 2015 Dec 11. *co-
  • 5) Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK. Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB (2016)
  • PD-L1 expression and prognostic impact in glioblastoma
  • Neuro Oncol, 2016 Feb;18(2):195-205, doi: 10.1093/neuonc/nov172. Epub 2015 Aug 30
  • 6) Nduom EK, Weller M, Heimberger AB (2015)
  • Immunosuppressive mechanisms in glioblastoma
  • Neuro Oncol, 2015 Nov;17 Suppl 7:vii9-vii14, doi: 10.1093/neuonc/nov151
  • 7) Nduom EK, Yang C, Merrill MJ, Zhuang Z, Lonser RR. Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms (2013)
  • Characterization of the blood-brain barrier of metastatic and primary malignant neoplasms
  • J Neurosurg, 2013 Aug;119(2):427-33, doi: 10.3171/2013.3.JNS122226. Epub 2013 Apr 26
  • 8) Nduom EK, Sribnick EA, Ormond DR, Hadjipanayis CG (2013)
  • Neuroendoscopic Resection of Intraventricular Tumors and Cysts through a Working Channel with a Variable Aspiration Tissue Resector: A Feasibility and Safety Study
  • Minim Invasive Surg, 2013;2013:471805, doi: 10.1155/2013/471805. Epub 2013 Jun 13
  • 9) Nduom EK, Hadjipanayis CG, Van Meir EG (2012)
  • Glioblastoma Stem-Like Cells: Implications for Pathogenesis and Treatment
  • Cancer J, 2012 Jan;18(1):100-6
  • 10) Platt S, Nduom E, Kent M, Freeman C, Machaidze R, Kaluzova M, Wang L, Mao H, Hadjipanayis CG (2012)
  • Canine model of convection-enhanced delivery of cetuximab-conjugated iron-oxide nanoparticles monitored with magnetic resonance imaging
  • Clin Neurosurg, 2012;59, 107-13
  • 11) Nduom EK, Walbridge S, Lonser RR (2012)
  • Comparison of Pulsed and Continuous Convective Flow for Central Nervous System Infusion
  • J Neurosurg, 2012 Oct 12 J Neurosurg, 2012 Dec;117(6):1150-4. doi: 10.3171/2012.9.JNS125
  • 12) Oddo M, Nduom E, Frangos S, MacKenzie L, Chen I, Maloney-Wilensky E, Kofke WA, Levine JM, LeRoux PD (2010)
  • Acute lung injury is an independent risk factor for brain hypoxia after severe traumatic brain injury
  • Neurosurgery, 2010 Aug;67(2), 338-44
View Pubmed Publication